Skip to main content
. Author manuscript; available in PMC: 2017 Jun 15.
Published in final edited form as: Clin Cancer Res. 2016 Feb 12;22(12):2885–2896. doi: 10.1158/1078-0432.CCR-15-2163

Figure 1.

Figure 1

Figure 1

Figure 1

(A) Measured absorbance of patient plasma in ELISA assay against angiopoietins 1 (Ang1) and 2 (Ang2) vs. week from the time of initial vaccination in patients with recurrent malignant glioma. The blue dashed vertical lines denote the timepoint of the last dose of vaccine per patient.

The aggregate time course and magnitude of anti-Ang1 antibodies (B) and anti-Ang2 antibodies (C) are represented. Vaccinated patient plasma more consistently registered responses to Ang2 peptide, and these were typically of greater intensity than responses to Ang1. Arrows denote delivery of vaccine.